381 related articles for article (PubMed ID: 22494466)
21. Pharmacotherapy for Parkinson's disease.
Chen JJ; Swope DM
Pharmacotherapy; 2007 Dec; 27(12 Pt 2):161S-173S. PubMed ID: 18041936
[TBL] [Abstract][Full Text] [Related]
22. Design, synthesis, and preliminary pharmacological evaluation of new imidazolinones as L-DOPA prodrugs.
Giorgioni G; Claudi F; Ruggieri S; Ricciutelli M; Palmieri GF; Di Stefano A; Sozio P; Cerasa LS; Chiavaroli A; Ferrante C; Orlando G; Glennon RA
Bioorg Med Chem; 2010 Mar; 18(5):1834-43. PubMed ID: 20153654
[TBL] [Abstract][Full Text] [Related]
23. [Treatment of motor symptoms in Parkinson's disease].
Morís-De la Tassa G; Arias-Rodríguez M
Rev Neurol; 2009 Jan; 48 Suppl 1():S27-31. PubMed ID: 19222012
[TBL] [Abstract][Full Text] [Related]
24. Advances in prodrug design for Parkinson's disease.
Cacciatore I; Ciulla M; Marinelli L; Eusepi P; Di Stefano A
Expert Opin Drug Discov; 2018 Apr; 13(4):295-305. PubMed ID: 29361853
[TBL] [Abstract][Full Text] [Related]
25. Drugs for Parkinson's disease.
Cranwell-Bruce LA
Medsurg Nurs; 2010; 19(6):347-9, 355; quiz 350. PubMed ID: 21337993
[No Abstract] [Full Text] [Related]
26. Role of COMT inhibitors and dopamine agonists in the treatment of motor fluctuations.
Widnell KL; Comella C
Mov Disord; 2005; 20 Suppl 11():S30-7. PubMed ID: 15822107
[TBL] [Abstract][Full Text] [Related]
27. Drugs for Parkinson's disease.
Treat Guidel Med Lett; 2011 Jan; 9(101):1-6; quiz 2 p following 6. PubMed ID: 21304446
[No Abstract] [Full Text] [Related]
28. Parkinson's disease therapy: treatment of early and late disease.
Jankovic J
Chin Med J (Engl); 2001 Mar; 114(3):227-34. PubMed ID: 11780303
[TBL] [Abstract][Full Text] [Related]
29. Treatment of Parkinson's disease.
Hely MA; Fung VS; Morris JG
J Clin Neurosci; 2000 Nov; 7(6):484-94. PubMed ID: 11029227
[TBL] [Abstract][Full Text] [Related]
30. New drugs in the treatment of Parkinson's disease. An introduction.
Bracco F
Adv Neurol; 1996; 69():513-7. PubMed ID: 8615173
[No Abstract] [Full Text] [Related]
31. L-dopa therapy for Parkinson's disease: past, present, and future.
Nagatsua T; Sawadab M
Parkinsonism Relat Disord; 2009 Jan; 15 Suppl 1():S3-8. PubMed ID: 19131039
[TBL] [Abstract][Full Text] [Related]
32. New drugs in the future treatment of Parkinson's disease.
Djaldetti R; Melamed E
J Neurol; 2002 Sep; 249 Suppl 2():II30-5. PubMed ID: 12375061
[TBL] [Abstract][Full Text] [Related]
33. Clinical implications of irregular ADMET properties with levodopa and other antiparkinson's drugs.
Dézsi L; Vécsei L
Expert Opin Drug Metab Toxicol; 2014 Mar; 10(3):409-24. PubMed ID: 24437461
[TBL] [Abstract][Full Text] [Related]
34. Recent advances in Parkinson's disease therapy: use of monoamine oxidase inhibitors.
Henchcliffe C; Schumacher HC; Burgut FT
Expert Rev Neurother; 2005 Nov; 5(6):811-21. PubMed ID: 16274338
[TBL] [Abstract][Full Text] [Related]
35. Lipid nanocarriers containing a levodopa prodrug with potential antiparkinsonian activity.
Ravani L; Sarpietro MG; Esposito E; Di Stefano A; Sozio P; Calcagno M; Drechsler M; Contado C; Longo F; Giuffrida MC; Castelli F; Morari M; Cortesi R
Mater Sci Eng C Mater Biol Appl; 2015 Mar; 48():294-300. PubMed ID: 25579926
[TBL] [Abstract][Full Text] [Related]
36. Advances in the delivery of treatments for Parkinson's disease.
Johnston TH; Fox SH; Brotchie JM
Expert Opin Drug Deliv; 2005 Nov; 2(6):1059-73. PubMed ID: 16296809
[TBL] [Abstract][Full Text] [Related]
37. Pharmacologic treatment of advanced Parkinson's disease: a meta-analysis of COMT inhibitors and MAO-B inhibitors.
Talati R; Reinhart K; Baker W; White CM; Coleman CI
Parkinsonism Relat Disord; 2009 Aug; 15(7):500-5. PubMed ID: 19167259
[TBL] [Abstract][Full Text] [Related]
38. [Current preclinical findings on substances against Parkinson's disease].
Gerlach M; Riederer P
Nervenarzt; 2003 Mar; 74 Suppl 1():S2-6. PubMed ID: 12624677
[TBL] [Abstract][Full Text] [Related]
39. Design, synthesis and biological evaluation of L-dopa amide derivatives as potential prodrugs for the treatment of Parkinson's disease.
Zhou T; Hider RC; Jenner P; Campbell B; Hobbs CJ; Rose S; Jairaj M; Tayarani-Binazir KA; Syme A
Eur J Med Chem; 2010 Sep; 45(9):4035-42. PubMed ID: 20646792
[TBL] [Abstract][Full Text] [Related]
40. Introductory remarks: Catechol-O-methyltransferase inhibition--an innovative approach to enhance L-dopa therapy in Parkinson's disease with dual enzyme inhibition.
Nissinen E
Int Rev Neurobiol; 2010; 95():1-5. PubMed ID: 21095456
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
